When was Terapet founded?

Terapet was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Terapet located?

Terapet is headquartered in Geneva, Switzerland.

Who is the current CEO of Terapet?

Christina Vallgren of Terapet. They have also founded 1 company.

How many employees does Terapet have?

As of Jun 30, 2026, the latest employee count at Terapet is 14.

Is Terapet a funded company?

Terapet is a funded company, having raised a total of $3.75M across 10 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 04, 2019.

When was the latest funding round of Terapet?

Terapet's latest funding was a $***** Grant (prize money) round on Mar 01, 2024, with participation from 1 investor. Its primary sector is Oncology. In Switzerland, the Oncology sector has seen $76.2M in funding in 2026 to date.

Where does Terapet rank among its competitors?

Terapet ranks 3rd amongst 14 active competitors, of which 7 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Leo Cancer Care, which secured $65M in Jul, 2026.

Who are the top competitors of Terapet?

Terapet's top competitors include Varian Medical Systems, Leo Cancer Care and P-Cure. Among them, Leo Cancer Care secured the most recent funding round in July, 2026.

Terapet - 2026 Company Profile, Team, Funding & Competitors

Terapet is a seed company based in Geneva (Switzerland), founded in 2019 by Marcus palm, Christina Vallgren and Raymond Miralbell. It operates as a Developer of integrated imaging solutions for proton therapy and nuclear medicine. Terapet has raised $3.75M in funding from investors like Nina Capital, Fongit and Fongit Seed Invest. The company has 14 active competitors, including 7 funded and 2 that have exited. Its top competitors include companies like Varian Medical Systems, Leo Cancer Care and P-Cure.

Company Details

Developer of integrated imaging solutions for proton therapy and nuclear medicine. It develops innovative platform technology for imaging in nuclear medicine, advancing proton therapy and nuclear imaging. The company's products enable quality and new clinical nuclear imaging in patient diagnosis and treatment, aiming to become a leading choice for radiotherapy and precision medicine. Its mission is to use its platform technology to create integrated imaging solutions that improve proton therapy, nuclear imaging, and precision medicine.

Website: terapet.ch
Social
Email ID: *****@terapet.ch

Key Metrics

Founded Year

2019

Location

Geneva, Switzerland

Stage

Seed

Total Funding

$3.75M in 10 rounds

Latest Funding Round

Grant (prize money), Mar 01, 2024, $*****

Investors

Nina Capital & 11 more

Ranked

3^rd among 14 active competitors

Employee Count

14 as on Jun 30, 2026

Similar Companies

Varian Medical Systems & 13 more

View Terapet's full profile

Terapet has raised a total funding of $3.75M over 10 rounds. Its first funding round was on Oct 04, 2019. Its latest funding round was a Grant (prize money) round on Mar 01, 2024 for $*****. 1 investor participated in its latest round. Terapet has 12 institutional investors.

Here is the list of recent funding rounds of Terapet:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2024	9488431	Grant (prize money)	1842294	8363094	5112027	7792108
Oct 13, 2023	8033631	Grant (prize money)	6805561	3869586	3271669	Innosuisse
Jun 22, 2023	8437670	Grant (prize money)	4095915	9813613	4296421	Innosuisse

Access funding benchmarks and valuations. Sign up today!

View details of Terapet's funding rounds and investors

The founders of Terapet are Marcus palm, Christina Vallgren and Raymond Miralbell. Christina Vallgren is the CEO of Terapet.

Here are the details of Terapet's key team members:

Marcus palm: Co-Founder & CTO of Terapet. They serve on the board of 1 company.
Contact Info: 1 email address
Christina Vallgren: Co-Founder & CEO of Terapet. They serve on the board of 1 company.
Contact Info: 1 email address
Raymond Miralbell: Co-Founder & CSO of Terapet.
Contact Info: 1 email address

Terapet's Board of Directors

Terapet's board has 5 active members. Marcus palm, Christina Vallgren and Rolf Lewensohn are part of team and Mark Plesko and Giovanni Leo are independent board members.

Here is the list of Terapet's board of directors:

Name	Type	Representing	Status	Duration
Marcus palm	Team	-	Current	-
Christina Vallgren	Team	-	Current	-
bceegqp	Team	-	Current	3y 4m
Mark Plesko	Independent board member	-	Current	-
cpqrffm	Independent board member	-	Current	5y 9m

View details of Terapet's Founder profiles and Board Members

Terapet's employee count trend

Terapet has 14 employees as of Jun 26. Here is Terapet's employee count trend over the years:

Uncover Terapet's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Terapet include Varian Medical Systems, Leo Cancer Care and P-Cure. Here is the list of Top 10 competitors of Terapet, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Varian Medical Systems 1948, Palo Alto (United States), Acquired	Provider and manufacturer of radiotherapy software and hardware solutions for professionals	-	Accelmed, OSTI & 2 others	61/100
2nd	Leo Cancer Care 2014, Crawley (United Kingdom), Series D	Manufacturer of upright patient positioning systems for radiation therapy treatments	$130M	Catalio Capital Management, WARF & 13 others	59/100
3rd	Terapet 2019, Geneva (Switzerland), Seed	Developer of integrated imaging solutions for proton therapy and nuclear medicine	$3.75M	Nina Capital, Eureka & 10 others	51/100
4th	P-Cure 2007, Lod (Israel), Series B	Imaging-based proton radiation therapy for cancer treatment	$30M	-	51/100
5th	Advanced Oncotherapy 1994, London (United Kingdom), Public	Provider of proton beam therapy system for the treatment of cancer	-	DNCA Finance, Aktiebolaget Segulah & 1 others	43/100
6th	HIL Medical 2010, Jerusalem (Israel), Series C	Developer of proton-beam radiotherapy device to treat solid tumors	$3.15M	Integra Holdings, EIC Fund & 3 others	38/100
7th	Provision Healthcare 2005, Knoxville (United States), Series B	Innovating cancer care with advanced proton therapy solutions and patient-centric approach	$30.4M	-	38/100
8th	B dot Medical 2017, Edogawa City (Japan), Series B	Developer of proton beam therapeutic devices for the treatment of cancer	$22M	Pegasus Tech Ventures, Mitsubishi UFJ Capital ... & 2 others	35/100
9th	Shanghai Aipqiang Particle Equipment 2012, Shanghai (China), Series A	Provider of proton therapy systems and related particle equipment	$6.29M	United Imaging Healthcare	29/100
10th	Proton Therapy Partners 2018, Wayne (United States), Funding Raised	Developer of proton therapy for treating cancer	-	Concord Health Partners	26/100